Active Ingredient History
Trimetazidine is a drug for angina pectoris sold under many brand names. Trimetazidine is described as the first cytoprotective anti-ischemic agent developed and marketed by Laboratoires Servier (France). It is an anti-ischemic (antianginal) metabolic agent of the fatty acid oxidation inhibitor class, meaning that it improves myocardial glucose utilization through inhibition of fatty acid metabolism. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Kidney Injury (Phase 4)
Acute-On-Chronic Liver Failure (Phase 1)
Amyotrophic Lateral Sclerosis (Phase 2)
Angina, Unstable (Phase 4)
Blood Platelet Disorders (Phase 2)
Carcinoma, Hepatocellular (Phase 3)
Cardiomyopathy, Hypertrophic (Phase 2)
Cardiotoxicity (Phase 2/Phase 3)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 4)
COVID-19 (Phase 2)
Diabetes Mellitus (Phase 3)
Diabetes Mellitus, Type 2 (Phase 4)
Diabetic Cardiomyopathies (Phase 2)
Diabetic Nephropathies (Phase 2)
Heart Diseases (Phase 4)
Heart Failure (Phase 1)
Heart Failure, Diastolic (Phase 4)
Hypertension, Pulmonary (Phase 2/Phase 3)
Medicine, Chinese Traditional (Phase 4)
Microcirculation (Phase 4)
Motor Neuron Disease (Phase 2)
Myocardium (Phase 2)
Neoplasms (Phase 1)
Non-alcoholic Fatty Liver Disease (Phase 2)
Pathology (Phase 4)
Percutaneous Coronary Intervention (Phase 4)
Respiratory Distress Syndrome (Phase 2)
Vascular Resistance (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue